INT787

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 1978
Last Reported 2010
Negated 1
Speculated 2
Reported most in Abstract
Documents 31
Total Number 33
Disease Relevance 12.36
Pain Relevance 11.55

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nuclear envelope (Ptgs1) aging (Ptgs1) Golgi apparatus (Ptgs1)
endoplasmic reticulum (Ptgs1) cytoplasm (Ptgs1) lipid binding (Ptgs1)
Anatomy Link Frequency
spinal 3
muscle 2
visceral 1
plasma 1
urinary bladder 1
Ptgs1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
substance P 4 100.00 Very High Very High Very High
excitatory amino acid 3 100.00 Very High Very High Very High
aspirin 2 100.00 Very High Very High Very High
cINOD 52 99.92 Very High Very High Very High
cOX1 9 99.82 Very High Very High Very High
COX2 9 99.82 Very High Very High Very High
Pain 18 99.68 Very High Very High Very High
Hyperalgesia 8 99.68 Very High Very High Very High
qutenza 25 99.62 Very High Very High Very High
Inflammation 25 99.40 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 50 99.80 Very High Very High Very High
Hyperalgesia 18 99.68 Very High Very High Very High
Irritable Bowel Syndrome /

Irritable Bowel Syndrome Super / Visceral Pain

1 99.26 Very High Very High Very High
Diabetes Mellitus 19 99.20 Very High Very High Very High
Hemolysis 12 98.88 Very High Very High Very High
Cough 22 97.52 Very High Very High Very High
Osteoarthritis 14 97.44 Very High Very High Very High
Nephrotoxicity 1 97.20 Very High Very High Very High
Hypersensitivity 2 97.00 Very High Very High Very High
Temporomandibular Joint Syndrome 8 96.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results demonstrate that ONOO- has significant pulmonary vasoconstrictor, systemic vasodepressor, and vasodilator activity; that short-term repeated exposure does impair vascular responsiveness; and that responses to ONOO- are not dependent on cyclooxygenase product release.
Localization (release) of cyclooxygenase product
1) Confidence 0.80 Published 2004 Journal J. Appl. Physiol. Section Abstract Doc Link 14715677 Disease Relevance 0.08 Pain Relevance 0.04
With the S(+) enantiomer and the racemate dose-dependent inhibition of release of cyclooxygenase products of arachidonate metabolism in all tissues tested was observed, while release of leukotriene (LT) C4 was inhibited in gastric mucosa, but not in jejunum and lung.
Localization (release) of cyclooxygenase in lung
2) Confidence 0.80 Published 1991 Journal Prostaglandins Section Abstract Doc Link 1801061 Disease Relevance 0.10 Pain Relevance 0
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Localization (administration) of cyclooxygenase-1
3) Confidence 0.73 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Localization (administration) of cyclooxygenase
4) Confidence 0.73 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
In the case of compounds provoking non-allergic hypersensitivity reactions, cross-reactivity is explained by a common pharmacological characteristic, such as the inhibitory effect of non-steroidal anti-inflammatory drugs on cyclooxygenase-1 and the capability of muscle relaxants or contrast media to release histamine through a non-immunologic mechanism.
Localization (release) of cyclooxygenase-1 in muscle associated with inflammation, hypersensitivity and cinod
5) Confidence 0.73 Published 2005 Journal Toxicology Section Abstract Doc Link 15767031 Disease Relevance 0.29 Pain Relevance 0.16
Hyperalgesic behavior in diabetic rats is associated with both increased cyclooxygenase-2 protein and cyclooxygenase-mediated PGE(2) release.
Localization (release) of cyclooxygenase associated with hyperalgesia and diabetes mellitus
6) Confidence 0.72 Published 2002 Journal Diabetes Section Abstract Doc Link 12086957 Disease Relevance 0.72 Pain Relevance 0.47
Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats.
Localization (release) of cyclooxygenase in spinal associated with hyperalgesia, diabetes mellitus and cox1
7) Confidence 0.72 Published 2002 Journal Diabetes Section Title Doc Link 12086957 Disease Relevance 0.75 Pain Relevance 0.55
Hyperalgesic behavior in diabetic rats is associated with both increased cyclooxygenase-2 protein and cyclooxygenase-mediated PGE(2) release.
Localization (release) of cyclooxygenase associated with hyperalgesia and diabetes mellitus
8) Confidence 0.72 Published 2002 Journal Diabetes Section Abstract Doc Link 12086957 Disease Relevance 0.71 Pain Relevance 0.47
Furthermore, the effect of a high dose of 25 mg/kg of the S(+) enantiomer on release of cyclooxygenase products from the various tissues was much longer lasting than that of an identical dose of the R(-) enantiomer.
Localization (release) of cyclooxygenase
9) Confidence 0.70 Published 1991 Journal Prostaglandins Section Abstract Doc Link 1801061 Disease Relevance 0.21 Pain Relevance 0.10
The decreased relaxation by BK in anococcygeus muscle did not occur by the release of cyclooxygenase products or tachykinins from tracheal epithelium, but it may have occurred by the contractile action of lipoxygenase product secreted by nonepithelial sources.
Localization (release) of cyclooxygenase in muscle associated with bradykinin
10) Confidence 0.62 Published 1998 Journal Gen. Pharmacol. Section Abstract Doc Link 9522162 Disease Relevance 0 Pain Relevance 0.48
CONCLUSIONS: This study identifies an early neutrophil-independent phase of indomethacin-induced enteropathy that involves rapid cyclooxygenase inhibition and both microvascular and smooth muscle changes.


Neg (inhibition) Localization (inhibition) of cyclooxygenase in smooth muscle
11) Confidence 0.43 Published 1994 Journal Gastroenterology Section Body Doc Link 8119525 Disease Relevance 0 Pain Relevance 0
The effect of barakol was partly mediated by the stimulation of submucosal nerves and through the release of cyclooxygenase metabolites.
Localization (release) of cyclooxygenase in nerves
12) Confidence 0.40 Published 2005 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15870391 Disease Relevance 0 Pain Relevance 0.09
Pharmacological characterization of this behavior has implicated the spinal release of excitatory amino acids (EAAs) and cyclooxygenase (COX) products.
Localization (release) of cyclooxygenase in spinal associated with excitatory amino acid
13) Confidence 0.39 Published 1995 Journal J. Neurosci. Section Abstract Doc Link 7722627 Disease Relevance 0 Pain Relevance 0.19
These results suggest that stonefish venom may cause the release of acetylcholine, substance P, and cyclooxygenase products, or contain components which act at these receptors.
Localization (release) of cyclooxygenase associated with substance p
14) Confidence 0.39 Published 1994 Journal Toxicon Section Abstract Doc Link 7846690 Disease Relevance 0.06 Pain Relevance 0.29
In addition the venom was found to cause the release of cyclooxygenase products and to contain a heat-sensitive hemolytic factor.
Localization (release) of cyclooxygenase
15) Confidence 0.36 Published 1994 Journal Nat. Toxins Section Abstract Doc Link 8032693 Disease Relevance 0.24 Pain Relevance 0.07
These observations support the body of literature that indicate that sustained small fiber input yields a hyperalgesia through activation of spinal NMDA and NK1 receptors and that in turn a portion of this action is mediated by the spinal release of cyclooxygenase products.
Localization (release) of cyclooxygenase in spinal associated with hyperalgesia
16) Confidence 0.35 Published 1993 Journal Agents Actions Suppl. Section Abstract Doc Link 8317344 Disease Relevance 0.26 Pain Relevance 0.43
With the S(+) enantiomer and the racemate dose-dependent inhibition of release of cyclooxygenase products of arachidonate metabolism in all tissues tested was observed, while release of leukotriene (LT) C4 was inhibited in gastric mucosa, but not in jejunum and lung.
Localization (release) of cyclooxygenase in jejunum
17) Confidence 0.27 Published 1991 Journal Prostaglandins Section Abstract Doc Link 1801061 Disease Relevance 0.10 Pain Relevance 0
Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion.
Localization (secretion) of cyclooxygenase associated with cox1
18) Confidence 0.22 Published 2001 Journal J. Physiol. Pharmacol. Section Title Doc Link 11785774 Disease Relevance 0 Pain Relevance 0.49
Cyclooxygenase products are released by chronic airway inflammation.
Localization (released) of Cyclooxygenase associated with inflammation
19) Confidence 0.16 Published 1995 Journal Eur. Respir. J. Section Abstract Doc Link 8575575 Disease Relevance 0.91 Pain Relevance 0.33
Differential distribution of cytochrome P450 and prostaglandin endoperoxide synthetase and each enzyme's preference for either cumene hydroperoxide or T-butyl hydroperoxide enabled the present investigation to distinguish their respective contributions in the cooxidative activation of paracetamol.
Localization (distribution) of prostaglandin endoperoxide synthetase associated with paracetamol
20) Confidence 0.14 Published 1981 Journal Res. Commun. Chem. Pathol. Pharmacol. Section Abstract Doc Link 6797006 Disease Relevance 0 Pain Relevance 0.69

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox